nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—FGFR2—stomach cancer	0.4	0.678	CbGaD
Thalidomide—TNF—stomach cancer	0.129	0.219	CbGaD
Thalidomide—PTGS2—stomach cancer	0.0612	0.104	CbGaD
Thalidomide—CYP2C9—Capecitabine—stomach cancer	0.0106	0.26	CbGbCtD
Thalidomide—CYP3A5—Irinotecan—stomach cancer	0.00975	0.239	CbGbCtD
Thalidomide—CYP3A5—Docetaxel—stomach cancer	0.00715	0.176	CbGbCtD
Thalidomide—CYP1A2—Fluorouracil—stomach cancer	0.00696	0.171	CbGbCtD
Thalidomide—CYP2C9—Fluorouracil—stomach cancer	0.00628	0.154	CbGbCtD
Thalidomide—NFKB1—hematopoietic system—stomach cancer	0.00195	0.0444	CbGeAlD
Thalidomide—CRBN—hematopoietic system—stomach cancer	0.00164	0.0373	CbGeAlD
Thalidomide—FGFR2—hematopoietic system—stomach cancer	0.00147	0.0334	CbGeAlD
Thalidomide—NFKB1—lymphoid tissue—stomach cancer	0.00138	0.0313	CbGeAlD
Thalidomide—TNF—lymph node—stomach cancer	0.00136	0.031	CbGeAlD
Thalidomide—NFKB1—digestive system—stomach cancer	0.00136	0.0309	CbGeAlD
Thalidomide—FGFR2—epithelium—stomach cancer	0.00134	0.0305	CbGeAlD
Thalidomide—CRBN—pancreas—stomach cancer	0.00133	0.0303	CbGeAlD
Thalidomide—FGFR2—smooth muscle tissue—stomach cancer	0.00129	0.0294	CbGeAlD
Thalidomide—NFKB1—bone marrow—stomach cancer	0.00125	0.0285	CbGeAlD
Thalidomide—Pomalidomide—TNF—stomach cancer	0.00116	0.326	CrCbGaD
Thalidomide—CRBN—lymphoid tissue—stomach cancer	0.00115	0.0262	CbGeAlD
Thalidomide—CRBN—digestive system—stomach cancer	0.00114	0.0259	CbGeAlD
Thalidomide—NFKB1—endocrine gland—stomach cancer	0.00112	0.0255	CbGeAlD
Thalidomide—CRBN—bone marrow—stomach cancer	0.00105	0.0239	CbGeAlD
Thalidomide—FGFR2—digestive system—stomach cancer	0.00102	0.0232	CbGeAlD
Thalidomide—NFKB1—liver—stomach cancer	0.00101	0.023	CbGeAlD
Thalidomide—CRBN—endocrine gland—stomach cancer	0.000941	0.0214	CbGeAlD
Thalidomide—PTGS1—blood vessel—stomach cancer	0.000876	0.0199	CbGeAlD
Thalidomide—CRBN—liver—stomach cancer	0.000849	0.0193	CbGeAlD
Thalidomide—FGFR2—endocrine gland—stomach cancer	0.000843	0.0192	CbGeAlD
Thalidomide—PTGS2—blood vessel—stomach cancer	0.000838	0.019	CbGeAlD
Thalidomide—PTGS2—gall bladder—stomach cancer	0.000788	0.0179	CbGeAlD
Thalidomide—NFKB1—lymph node—stomach cancer	0.000776	0.0177	CbGeAlD
Thalidomide—FGFR2—liver—stomach cancer	0.00076	0.0173	CbGeAlD
Thalidomide—Menadione—MTHFR—stomach cancer	0.000674	0.19	CrCbGaD
Thalidomide—CYP2C19—hematopoietic system—stomach cancer	0.000659	0.015	CbGeAlD
Thalidomide—CRBN—lymph node—stomach cancer	0.000651	0.0148	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—stomach cancer	0.000592	0.167	CrCbGaD
Thalidomide—Menadione—CYP2A6—stomach cancer	0.000577	0.162	CrCbGaD
Thalidomide—Pomalidomide—PTGS2—stomach cancer	0.00055	0.155	CrCbGaD
Thalidomide—CYP1A2—hematopoietic system—stomach cancer	0.000538	0.0122	CbGeAlD
Thalidomide—CYP1A1—hematopoietic system—stomach cancer	0.000531	0.0121	CbGeAlD
Thalidomide—CYP3A5—hematopoietic system—stomach cancer	0.000519	0.0118	CbGeAlD
Thalidomide—CYP2C9—hematopoietic system—stomach cancer	0.000511	0.0116	CbGeAlD
Thalidomide—CYP1A1—epithelium—stomach cancer	0.000486	0.011	CbGeAlD
Thalidomide—CYP2E1—hematopoietic system—stomach cancer	0.000484	0.011	CbGeAlD
Thalidomide—PTGS1—hematopoietic system—stomach cancer	0.000467	0.0106	CbGeAlD
Thalidomide—CYP2C19—digestive system—stomach cancer	0.000458	0.0104	CbGeAlD
Thalidomide—PTGS2—hematopoietic system—stomach cancer	0.000446	0.0101	CbGeAlD
Thalidomide—PTGS1—epithelium—stomach cancer	0.000427	0.0097	CbGeAlD
Thalidomide—CYP3A5—pancreas—stomach cancer	0.000423	0.00962	CbGeAlD
Thalidomide—PTGS1—smooth muscle tissue—stomach cancer	0.000411	0.00935	CbGeAlD
Thalidomide—PTGS2—epithelium—stomach cancer	0.000408	0.00927	CbGeAlD
Thalidomide—PTGS2—smooth muscle tissue—stomach cancer	0.000393	0.00893	CbGeAlD
Thalidomide—CYP2C19—endocrine gland—stomach cancer	0.000379	0.00862	CbGeAlD
Thalidomide—CYP1A2—digestive system—stomach cancer	0.000374	0.00852	CbGeAlD
Thalidomide—CYP1A1—digestive system—stomach cancer	0.000369	0.0084	CbGeAlD
Thalidomide—PTGS2—pancreas—stomach cancer	0.000363	0.00826	CbGeAlD
Thalidomide—CYP3A5—digestive system—stomach cancer	0.000361	0.00821	CbGeAlD
Thalidomide—CYP2C9—digestive system—stomach cancer	0.000355	0.00808	CbGeAlD
Thalidomide—CYP2C19—liver—stomach cancer	0.000342	0.00777	CbGeAlD
Thalidomide—CYP2E1—lymphoid tissue—stomach cancer	0.000341	0.00776	CbGeAlD
Thalidomide—CYP2E1—digestive system—stomach cancer	0.000337	0.00766	CbGeAlD
Thalidomide—PTGS1—digestive system—stomach cancer	0.000325	0.00738	CbGeAlD
Thalidomide—PTGS2—lymphoid tissue—stomach cancer	0.000314	0.00714	CbGeAlD
Thalidomide—PTGS2—digestive system—stomach cancer	0.00031	0.00705	CbGeAlD
Thalidomide—CYP1A2—endocrine gland—stomach cancer	0.000309	0.00704	CbGeAlD
Thalidomide—CYP1A1—endocrine gland—stomach cancer	0.000305	0.00694	CbGeAlD
Thalidomide—CYP3A5—endocrine gland—stomach cancer	0.000298	0.00679	CbGeAlD
Thalidomide—CYP2C9—endocrine gland—stomach cancer	0.000294	0.00668	CbGeAlD
Thalidomide—PTGS2—bone marrow—stomach cancer	0.000286	0.0065	CbGeAlD
Thalidomide—CYP1A2—liver—stomach cancer	0.000279	0.00634	CbGeAlD
Thalidomide—CYP2E1—endocrine gland—stomach cancer	0.000278	0.00633	CbGeAlD
Thalidomide—CYP1A1—liver—stomach cancer	0.000275	0.00626	CbGeAlD
Thalidomide—CYP3A5—liver—stomach cancer	0.000269	0.00612	CbGeAlD
Thalidomide—PTGS1—endocrine gland—stomach cancer	0.000268	0.0061	CbGeAlD
Thalidomide—CYP2C9—liver—stomach cancer	0.000265	0.00602	CbGeAlD
Thalidomide—PTGS2—endocrine gland—stomach cancer	0.000256	0.00583	CbGeAlD
Thalidomide—CYP2E1—liver—stomach cancer	0.000251	0.00571	CbGeAlD
Thalidomide—PTGS2—liver—stomach cancer	0.000231	0.00526	CbGeAlD
Thalidomide—CYP1A1—lymph node—stomach cancer	0.000211	0.0048	CbGeAlD
Thalidomide—PTGS1—lymph node—stomach cancer	0.000185	0.00422	CbGeAlD
Thalidomide—PTGS2—lymph node—stomach cancer	0.000177	0.00403	CbGeAlD
Thalidomide—Dyspepsia—Docetaxel—stomach cancer	4.7e-05	0.000262	CcSEcCtD
Thalidomide—Hepatitis—Doxorubicin—stomach cancer	4.69e-05	0.000261	CcSEcCtD
Thalidomide—Insomnia—Capecitabine—stomach cancer	4.68e-05	0.00026	CcSEcCtD
Thalidomide—Hypoaesthesia—Doxorubicin—stomach cancer	4.67e-05	0.00026	CcSEcCtD
Thalidomide—Rash—Fluorouracil—stomach cancer	4.66e-05	0.00026	CcSEcCtD
Thalidomide—Dermatitis—Fluorouracil—stomach cancer	4.66e-05	0.000259	CcSEcCtD
Thalidomide—Pharyngitis—Doxorubicin—stomach cancer	4.65e-05	0.000259	CcSEcCtD
Thalidomide—Paraesthesia—Capecitabine—stomach cancer	4.64e-05	0.000258	CcSEcCtD
Thalidomide—Decreased appetite—Docetaxel—stomach cancer	4.64e-05	0.000258	CcSEcCtD
Thalidomide—Headache—Fluorouracil—stomach cancer	4.63e-05	0.000258	CcSEcCtD
Thalidomide—Urinary tract disorder—Doxorubicin—stomach cancer	4.63e-05	0.000258	CcSEcCtD
Thalidomide—Oedema peripheral—Doxorubicin—stomach cancer	4.62e-05	0.000257	CcSEcCtD
Thalidomide—Dysgeusia—Methotrexate—stomach cancer	4.62e-05	0.000257	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Docetaxel—stomach cancer	4.61e-05	0.000257	CcSEcCtD
Thalidomide—Dyspnoea—Capecitabine—stomach cancer	4.61e-05	0.000257	CcSEcCtD
Thalidomide—Fatigue—Docetaxel—stomach cancer	4.6e-05	0.000256	CcSEcCtD
Thalidomide—Angiopathy—Epirubicin—stomach cancer	4.6e-05	0.000256	CcSEcCtD
Thalidomide—Urethral disorder—Doxorubicin—stomach cancer	4.6e-05	0.000256	CcSEcCtD
Thalidomide—Nausea—Irinotecan—stomach cancer	4.59e-05	0.000255	CcSEcCtD
Thalidomide—Immune system disorder—Epirubicin—stomach cancer	4.58e-05	0.000255	CcSEcCtD
Thalidomide—Mediastinal disorder—Epirubicin—stomach cancer	4.57e-05	0.000254	CcSEcCtD
Thalidomide—Pain—Docetaxel—stomach cancer	4.57e-05	0.000254	CcSEcCtD
Thalidomide—Constipation—Docetaxel—stomach cancer	4.57e-05	0.000254	CcSEcCtD
Thalidomide—Back pain—Methotrexate—stomach cancer	4.56e-05	0.000254	CcSEcCtD
Thalidomide—Dyspepsia—Capecitabine—stomach cancer	4.55e-05	0.000253	CcSEcCtD
Thalidomide—Chills—Epirubicin—stomach cancer	4.55e-05	0.000253	CcSEcCtD
Thalidomide—Arrhythmia—Epirubicin—stomach cancer	4.53e-05	0.000252	CcSEcCtD
Thalidomide—Visual impairment—Doxorubicin—stomach cancer	4.52e-05	0.000252	CcSEcCtD
Thalidomide—Decreased appetite—Capecitabine—stomach cancer	4.49e-05	0.00025	CcSEcCtD
Thalidomide—Alopecia—Epirubicin—stomach cancer	4.48e-05	0.000249	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Capecitabine—stomach cancer	4.46e-05	0.000248	CcSEcCtD
Thalidomide—Fatigue—Capecitabine—stomach cancer	4.46e-05	0.000248	CcSEcCtD
Thalidomide—Vision blurred—Methotrexate—stomach cancer	4.44e-05	0.000247	CcSEcCtD
Thalidomide—Mental disorder—Epirubicin—stomach cancer	4.44e-05	0.000247	CcSEcCtD
Thalidomide—Erythema multiforme—Doxorubicin—stomach cancer	4.43e-05	0.000247	CcSEcCtD
Thalidomide—Constipation—Capecitabine—stomach cancer	4.42e-05	0.000246	CcSEcCtD
Thalidomide—Pain—Capecitabine—stomach cancer	4.42e-05	0.000246	CcSEcCtD
Thalidomide—Malnutrition—Epirubicin—stomach cancer	4.41e-05	0.000246	CcSEcCtD
Thalidomide—Feeling abnormal—Docetaxel—stomach cancer	4.4e-05	0.000245	CcSEcCtD
Thalidomide—Nausea—Fluorouracil—stomach cancer	4.39e-05	0.000245	CcSEcCtD
Thalidomide—Eye disorder—Doxorubicin—stomach cancer	4.38e-05	0.000244	CcSEcCtD
Thalidomide—Ill-defined disorder—Methotrexate—stomach cancer	4.37e-05	0.000244	CcSEcCtD
Thalidomide—Tinnitus—Doxorubicin—stomach cancer	4.37e-05	0.000243	CcSEcCtD
Thalidomide—Gastrointestinal pain—Docetaxel—stomach cancer	4.37e-05	0.000243	CcSEcCtD
Thalidomide—Anaemia—Methotrexate—stomach cancer	4.36e-05	0.000243	CcSEcCtD
Thalidomide—Cardiac disorder—Doxorubicin—stomach cancer	4.35e-05	0.000242	CcSEcCtD
Thalidomide—Flatulence—Epirubicin—stomach cancer	4.35e-05	0.000242	CcSEcCtD
Thalidomide—Tension—Epirubicin—stomach cancer	4.33e-05	0.000241	CcSEcCtD
Thalidomide—Dysgeusia—Epirubicin—stomach cancer	4.32e-05	0.000241	CcSEcCtD
Thalidomide—Nervousness—Epirubicin—stomach cancer	4.29e-05	0.000239	CcSEcCtD
Thalidomide—Back pain—Epirubicin—stomach cancer	4.27e-05	0.000238	CcSEcCtD
Thalidomide—Feeling abnormal—Capecitabine—stomach cancer	4.26e-05	0.000237	CcSEcCtD
Thalidomide—Angiopathy—Doxorubicin—stomach cancer	4.26e-05	0.000237	CcSEcCtD
Thalidomide—Malaise—Methotrexate—stomach cancer	4.25e-05	0.000237	CcSEcCtD
Thalidomide—Muscle spasms—Epirubicin—stomach cancer	4.24e-05	0.000236	CcSEcCtD
Thalidomide—Immune system disorder—Doxorubicin—stomach cancer	4.24e-05	0.000236	CcSEcCtD
Thalidomide—Vertigo—Methotrexate—stomach cancer	4.24e-05	0.000236	CcSEcCtD
Thalidomide—Gastrointestinal pain—Capecitabine—stomach cancer	4.23e-05	0.000235	CcSEcCtD
Thalidomide—Mediastinal disorder—Doxorubicin—stomach cancer	4.23e-05	0.000235	CcSEcCtD
Thalidomide—Body temperature increased—Docetaxel—stomach cancer	4.22e-05	0.000235	CcSEcCtD
Thalidomide—Abdominal pain—Docetaxel—stomach cancer	4.22e-05	0.000235	CcSEcCtD
Thalidomide—Leukopenia—Methotrexate—stomach cancer	4.22e-05	0.000235	CcSEcCtD
Thalidomide—Chills—Doxorubicin—stomach cancer	4.21e-05	0.000234	CcSEcCtD
Thalidomide—Arrhythmia—Doxorubicin—stomach cancer	4.19e-05	0.000233	CcSEcCtD
Thalidomide—Vision blurred—Epirubicin—stomach cancer	4.16e-05	0.000231	CcSEcCtD
Thalidomide—Alopecia—Doxorubicin—stomach cancer	4.14e-05	0.000231	CcSEcCtD
Thalidomide—Cough—Methotrexate—stomach cancer	4.11e-05	0.000229	CcSEcCtD
Thalidomide—Mental disorder—Doxorubicin—stomach cancer	4.11e-05	0.000229	CcSEcCtD
Thalidomide—Urticaria—Capecitabine—stomach cancer	4.11e-05	0.000229	CcSEcCtD
Thalidomide—Ill-defined disorder—Epirubicin—stomach cancer	4.09e-05	0.000228	CcSEcCtD
Thalidomide—Abdominal pain—Capecitabine—stomach cancer	4.09e-05	0.000227	CcSEcCtD
Thalidomide—Body temperature increased—Capecitabine—stomach cancer	4.09e-05	0.000227	CcSEcCtD
Thalidomide—Convulsion—Methotrexate—stomach cancer	4.09e-05	0.000227	CcSEcCtD
Thalidomide—Malnutrition—Doxorubicin—stomach cancer	4.08e-05	0.000227	CcSEcCtD
Thalidomide—Anaemia—Epirubicin—stomach cancer	4.08e-05	0.000227	CcSEcCtD
Thalidomide—Agitation—Epirubicin—stomach cancer	4.06e-05	0.000226	CcSEcCtD
Thalidomide—Flatulence—Doxorubicin—stomach cancer	4.02e-05	0.000224	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—stomach cancer	4.01e-05	0.000223	CcSEcCtD
Thalidomide—Myalgia—Methotrexate—stomach cancer	4.01e-05	0.000223	CcSEcCtD
Thalidomide—Chest pain—Methotrexate—stomach cancer	4.01e-05	0.000223	CcSEcCtD
Thalidomide—Tension—Doxorubicin—stomach cancer	4.01e-05	0.000223	CcSEcCtD
Thalidomide—Dysgeusia—Doxorubicin—stomach cancer	4e-05	0.000223	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	3.99e-05	0.000222	CcSEcCtD
Thalidomide—Malaise—Epirubicin—stomach cancer	3.98e-05	0.000221	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—stomach cancer	3.97e-05	0.000221	CcSEcCtD
Thalidomide—Nervousness—Doxorubicin—stomach cancer	3.97e-05	0.000221	CcSEcCtD
Thalidomide—Vertigo—Epirubicin—stomach cancer	3.96e-05	0.000221	CcSEcCtD
Thalidomide—Syncope—Epirubicin—stomach cancer	3.96e-05	0.00022	CcSEcCtD
Thalidomide—Leukopenia—Epirubicin—stomach cancer	3.95e-05	0.00022	CcSEcCtD
Thalidomide—Back pain—Doxorubicin—stomach cancer	3.95e-05	0.00022	CcSEcCtD
Thalidomide—Hypersensitivity—Docetaxel—stomach cancer	3.93e-05	0.000219	CcSEcCtD
Thalidomide—Muscle spasms—Doxorubicin—stomach cancer	3.93e-05	0.000218	CcSEcCtD
Thalidomide—Palpitations—Epirubicin—stomach cancer	3.9e-05	0.000217	CcSEcCtD
Thalidomide—Confusional state—Methotrexate—stomach cancer	3.88e-05	0.000216	CcSEcCtD
Thalidomide—Loss of consciousness—Epirubicin—stomach cancer	3.88e-05	0.000216	CcSEcCtD
Thalidomide—Cough—Epirubicin—stomach cancer	3.85e-05	0.000214	CcSEcCtD
Thalidomide—Vision blurred—Doxorubicin—stomach cancer	3.85e-05	0.000214	CcSEcCtD
Thalidomide—Asthenia—Docetaxel—stomach cancer	3.83e-05	0.000213	CcSEcCtD
Thalidomide—Convulsion—Epirubicin—stomach cancer	3.82e-05	0.000213	CcSEcCtD
Thalidomide—Infection—Methotrexate—stomach cancer	3.82e-05	0.000213	CcSEcCtD
Thalidomide—Hypertension—Epirubicin—stomach cancer	3.81e-05	0.000212	CcSEcCtD
Thalidomide—Hypersensitivity—Capecitabine—stomach cancer	3.81e-05	0.000212	CcSEcCtD
Thalidomide—Ill-defined disorder—Doxorubicin—stomach cancer	3.79e-05	0.000211	CcSEcCtD
Thalidomide—Pruritus—Docetaxel—stomach cancer	3.78e-05	0.00021	CcSEcCtD
Thalidomide—Nervous system disorder—Methotrexate—stomach cancer	3.77e-05	0.00021	CcSEcCtD
Thalidomide—Anaemia—Doxorubicin—stomach cancer	3.77e-05	0.00021	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—stomach cancer	3.77e-05	0.00021	CcSEcCtD
Thalidomide—Arthralgia—Epirubicin—stomach cancer	3.76e-05	0.000209	CcSEcCtD
Thalidomide—Chest pain—Epirubicin—stomach cancer	3.76e-05	0.000209	CcSEcCtD
Thalidomide—Myalgia—Epirubicin—stomach cancer	3.76e-05	0.000209	CcSEcCtD
Thalidomide—Agitation—Doxorubicin—stomach cancer	3.75e-05	0.000209	CcSEcCtD
Thalidomide—Anxiety—Epirubicin—stomach cancer	3.74e-05	0.000208	CcSEcCtD
Thalidomide—Skin disorder—Methotrexate—stomach cancer	3.74e-05	0.000208	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	3.73e-05	0.000208	CcSEcCtD
Thalidomide—Hyperhidrosis—Methotrexate—stomach cancer	3.72e-05	0.000207	CcSEcCtD
Thalidomide—Discomfort—Epirubicin—stomach cancer	3.71e-05	0.000207	CcSEcCtD
Thalidomide—Asthenia—Capecitabine—stomach cancer	3.71e-05	0.000206	CcSEcCtD
Thalidomide—Malaise—Doxorubicin—stomach cancer	3.68e-05	0.000205	CcSEcCtD
Thalidomide—Dry mouth—Epirubicin—stomach cancer	3.67e-05	0.000205	CcSEcCtD
Thalidomide—Vertigo—Doxorubicin—stomach cancer	3.67e-05	0.000204	CcSEcCtD
Thalidomide—Anorexia—Methotrexate—stomach cancer	3.67e-05	0.000204	CcSEcCtD
Thalidomide—Syncope—Doxorubicin—stomach cancer	3.66e-05	0.000204	CcSEcCtD
Thalidomide—Pruritus—Capecitabine—stomach cancer	3.66e-05	0.000204	CcSEcCtD
Thalidomide—Leukopenia—Doxorubicin—stomach cancer	3.65e-05	0.000203	CcSEcCtD
Thalidomide—Diarrhoea—Docetaxel—stomach cancer	3.65e-05	0.000203	CcSEcCtD
Thalidomide—Confusional state—Epirubicin—stomach cancer	3.63e-05	0.000202	CcSEcCtD
Thalidomide—Palpitations—Doxorubicin—stomach cancer	3.61e-05	0.000201	CcSEcCtD
Thalidomide—Oedema—Epirubicin—stomach cancer	3.6e-05	0.0002	CcSEcCtD
Thalidomide—Hypotension—Methotrexate—stomach cancer	3.6e-05	0.0002	CcSEcCtD
Thalidomide—Loss of consciousness—Doxorubicin—stomach cancer	3.59e-05	0.0002	CcSEcCtD
Thalidomide—Infection—Epirubicin—stomach cancer	3.58e-05	0.000199	CcSEcCtD
Thalidomide—Cough—Doxorubicin—stomach cancer	3.56e-05	0.000198	CcSEcCtD
Thalidomide—Shock—Epirubicin—stomach cancer	3.54e-05	0.000197	CcSEcCtD
Thalidomide—Convulsion—Doxorubicin—stomach cancer	3.54e-05	0.000197	CcSEcCtD
Thalidomide—Diarrhoea—Capecitabine—stomach cancer	3.54e-05	0.000197	CcSEcCtD
Thalidomide—Nervous system disorder—Epirubicin—stomach cancer	3.53e-05	0.000197	CcSEcCtD
Thalidomide—Dizziness—Docetaxel—stomach cancer	3.53e-05	0.000197	CcSEcCtD
Thalidomide—Thrombocytopenia—Epirubicin—stomach cancer	3.53e-05	0.000196	CcSEcCtD
Thalidomide—Hypertension—Doxorubicin—stomach cancer	3.52e-05	0.000196	CcSEcCtD
Thalidomide—Tachycardia—Epirubicin—stomach cancer	3.51e-05	0.000196	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methotrexate—stomach cancer	3.51e-05	0.000195	CcSEcCtD
Thalidomide—Skin disorder—Epirubicin—stomach cancer	3.5e-05	0.000195	CcSEcCtD
Thalidomide—Hyperhidrosis—Epirubicin—stomach cancer	3.48e-05	0.000194	CcSEcCtD
Thalidomide—Insomnia—Methotrexate—stomach cancer	3.48e-05	0.000194	CcSEcCtD
Thalidomide—Chest pain—Doxorubicin—stomach cancer	3.48e-05	0.000193	CcSEcCtD
Thalidomide—Arthralgia—Doxorubicin—stomach cancer	3.48e-05	0.000193	CcSEcCtD
Thalidomide—Myalgia—Doxorubicin—stomach cancer	3.48e-05	0.000193	CcSEcCtD
Thalidomide—Anxiety—Doxorubicin—stomach cancer	3.46e-05	0.000193	CcSEcCtD
Thalidomide—Paraesthesia—Methotrexate—stomach cancer	3.46e-05	0.000192	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	3.45e-05	0.000192	CcSEcCtD
Thalidomide—Discomfort—Doxorubicin—stomach cancer	3.43e-05	0.000191	CcSEcCtD
Thalidomide—Anorexia—Epirubicin—stomach cancer	3.43e-05	0.000191	CcSEcCtD
Thalidomide—Dyspnoea—Methotrexate—stomach cancer	3.43e-05	0.000191	CcSEcCtD
Thalidomide—Somnolence—Methotrexate—stomach cancer	3.42e-05	0.00019	CcSEcCtD
Thalidomide—Dizziness—Capecitabine—stomach cancer	3.42e-05	0.00019	CcSEcCtD
Thalidomide—Dry mouth—Doxorubicin—stomach cancer	3.4e-05	0.000189	CcSEcCtD
Thalidomide—Vomiting—Docetaxel—stomach cancer	3.39e-05	0.000189	CcSEcCtD
Thalidomide—Dyspepsia—Methotrexate—stomach cancer	3.39e-05	0.000189	CcSEcCtD
Thalidomide—Rash—Docetaxel—stomach cancer	3.37e-05	0.000187	CcSEcCtD
Thalidomide—Hypotension—Epirubicin—stomach cancer	3.37e-05	0.000187	CcSEcCtD
Thalidomide—Dermatitis—Docetaxel—stomach cancer	3.36e-05	0.000187	CcSEcCtD
Thalidomide—Confusional state—Doxorubicin—stomach cancer	3.36e-05	0.000187	CcSEcCtD
Thalidomide—Decreased appetite—Methotrexate—stomach cancer	3.35e-05	0.000186	CcSEcCtD
Thalidomide—Headache—Docetaxel—stomach cancer	3.34e-05	0.000186	CcSEcCtD
Thalidomide—Oedema—Doxorubicin—stomach cancer	3.33e-05	0.000185	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Methotrexate—stomach cancer	3.32e-05	0.000185	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—stomach cancer	3.32e-05	0.000185	CcSEcCtD
Thalidomide—Infection—Doxorubicin—stomach cancer	3.31e-05	0.000184	CcSEcCtD
Thalidomide—Pain—Methotrexate—stomach cancer	3.29e-05	0.000183	CcSEcCtD
Thalidomide—Vomiting—Capecitabine—stomach cancer	3.29e-05	0.000183	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Epirubicin—stomach cancer	3.28e-05	0.000183	CcSEcCtD
Thalidomide—Shock—Doxorubicin—stomach cancer	3.28e-05	0.000182	CcSEcCtD
Thalidomide—Nervous system disorder—Doxorubicin—stomach cancer	3.27e-05	0.000182	CcSEcCtD
Thalidomide—Thrombocytopenia—Doxorubicin—stomach cancer	3.26e-05	0.000182	CcSEcCtD
Thalidomide—Rash—Capecitabine—stomach cancer	3.26e-05	0.000181	CcSEcCtD
Thalidomide—Insomnia—Epirubicin—stomach cancer	3.26e-05	0.000181	CcSEcCtD
Thalidomide—Dermatitis—Capecitabine—stomach cancer	3.26e-05	0.000181	CcSEcCtD
Thalidomide—Tachycardia—Doxorubicin—stomach cancer	3.25e-05	0.000181	CcSEcCtD
Thalidomide—Headache—Capecitabine—stomach cancer	3.24e-05	0.00018	CcSEcCtD
Thalidomide—Skin disorder—Doxorubicin—stomach cancer	3.24e-05	0.00018	CcSEcCtD
Thalidomide—Paraesthesia—Epirubicin—stomach cancer	3.23e-05	0.00018	CcSEcCtD
Thalidomide—Hyperhidrosis—Doxorubicin—stomach cancer	3.22e-05	0.000179	CcSEcCtD
Thalidomide—Dyspnoea—Epirubicin—stomach cancer	3.21e-05	0.000179	CcSEcCtD
Thalidomide—Somnolence—Epirubicin—stomach cancer	3.2e-05	0.000178	CcSEcCtD
Thalidomide—Anorexia—Doxorubicin—stomach cancer	3.18e-05	0.000177	CcSEcCtD
Thalidomide—Nausea—Docetaxel—stomach cancer	3.17e-05	0.000177	CcSEcCtD
Thalidomide—Feeling abnormal—Methotrexate—stomach cancer	3.17e-05	0.000177	CcSEcCtD
Thalidomide—Dyspepsia—Epirubicin—stomach cancer	3.17e-05	0.000176	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methotrexate—stomach cancer	3.15e-05	0.000175	CcSEcCtD
Thalidomide—Decreased appetite—Epirubicin—stomach cancer	3.13e-05	0.000174	CcSEcCtD
Thalidomide—Hypotension—Doxorubicin—stomach cancer	3.11e-05	0.000173	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Epirubicin—stomach cancer	3.11e-05	0.000173	CcSEcCtD
Thalidomide—Fatigue—Epirubicin—stomach cancer	3.1e-05	0.000173	CcSEcCtD
Thalidomide—Pain—Epirubicin—stomach cancer	3.08e-05	0.000171	CcSEcCtD
Thalidomide—Constipation—Epirubicin—stomach cancer	3.08e-05	0.000171	CcSEcCtD
Thalidomide—Nausea—Capecitabine—stomach cancer	3.07e-05	0.000171	CcSEcCtD
Thalidomide—Urticaria—Methotrexate—stomach cancer	3.06e-05	0.00017	CcSEcCtD
Thalidomide—Body temperature increased—Methotrexate—stomach cancer	3.04e-05	0.000169	CcSEcCtD
Thalidomide—Abdominal pain—Methotrexate—stomach cancer	3.04e-05	0.000169	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Doxorubicin—stomach cancer	3.04e-05	0.000169	CcSEcCtD
Thalidomide—Insomnia—Doxorubicin—stomach cancer	3.01e-05	0.000168	CcSEcCtD
Thalidomide—Paraesthesia—Doxorubicin—stomach cancer	2.99e-05	0.000167	CcSEcCtD
Thalidomide—Dyspnoea—Doxorubicin—stomach cancer	2.97e-05	0.000165	CcSEcCtD
Thalidomide—Feeling abnormal—Epirubicin—stomach cancer	2.97e-05	0.000165	CcSEcCtD
Thalidomide—Somnolence—Doxorubicin—stomach cancer	2.96e-05	0.000165	CcSEcCtD
Thalidomide—Gastrointestinal pain—Epirubicin—stomach cancer	2.94e-05	0.000164	CcSEcCtD
Thalidomide—Dyspepsia—Doxorubicin—stomach cancer	2.93e-05	0.000163	CcSEcCtD
Thalidomide—Decreased appetite—Doxorubicin—stomach cancer	2.9e-05	0.000161	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Doxorubicin—stomach cancer	2.88e-05	0.00016	CcSEcCtD
Thalidomide—Fatigue—Doxorubicin—stomach cancer	2.87e-05	0.00016	CcSEcCtD
Thalidomide—Urticaria—Epirubicin—stomach cancer	2.86e-05	0.000159	CcSEcCtD
Thalidomide—Pain—Doxorubicin—stomach cancer	2.85e-05	0.000159	CcSEcCtD
Thalidomide—Constipation—Doxorubicin—stomach cancer	2.85e-05	0.000159	CcSEcCtD
Thalidomide—Abdominal pain—Epirubicin—stomach cancer	2.85e-05	0.000158	CcSEcCtD
Thalidomide—Body temperature increased—Epirubicin—stomach cancer	2.85e-05	0.000158	CcSEcCtD
Thalidomide—Hypersensitivity—Methotrexate—stomach cancer	2.84e-05	0.000158	CcSEcCtD
Thalidomide—Asthenia—Methotrexate—stomach cancer	2.76e-05	0.000154	CcSEcCtD
Thalidomide—Feeling abnormal—Doxorubicin—stomach cancer	2.75e-05	0.000153	CcSEcCtD
Thalidomide—Gastrointestinal pain—Doxorubicin—stomach cancer	2.72e-05	0.000152	CcSEcCtD
Thalidomide—Pruritus—Methotrexate—stomach cancer	2.72e-05	0.000152	CcSEcCtD
Thalidomide—Hypersensitivity—Epirubicin—stomach cancer	2.65e-05	0.000148	CcSEcCtD
Thalidomide—Urticaria—Doxorubicin—stomach cancer	2.65e-05	0.000147	CcSEcCtD
Thalidomide—Abdominal pain—Doxorubicin—stomach cancer	2.63e-05	0.000147	CcSEcCtD
Thalidomide—Body temperature increased—Doxorubicin—stomach cancer	2.63e-05	0.000147	CcSEcCtD
Thalidomide—Diarrhoea—Methotrexate—stomach cancer	2.63e-05	0.000147	CcSEcCtD
Thalidomide—Asthenia—Epirubicin—stomach cancer	2.58e-05	0.000144	CcSEcCtD
Thalidomide—Pruritus—Epirubicin—stomach cancer	2.55e-05	0.000142	CcSEcCtD
Thalidomide—Dizziness—Methotrexate—stomach cancer	2.54e-05	0.000142	CcSEcCtD
Thalidomide—Diarrhoea—Epirubicin—stomach cancer	2.46e-05	0.000137	CcSEcCtD
Thalidomide—Hypersensitivity—Doxorubicin—stomach cancer	2.45e-05	0.000137	CcSEcCtD
Thalidomide—Vomiting—Methotrexate—stomach cancer	2.45e-05	0.000136	CcSEcCtD
Thalidomide—Rash—Methotrexate—stomach cancer	2.43e-05	0.000135	CcSEcCtD
Thalidomide—Dermatitis—Methotrexate—stomach cancer	2.42e-05	0.000135	CcSEcCtD
Thalidomide—Headache—Methotrexate—stomach cancer	2.41e-05	0.000134	CcSEcCtD
Thalidomide—Asthenia—Doxorubicin—stomach cancer	2.39e-05	0.000133	CcSEcCtD
Thalidomide—Dizziness—Epirubicin—stomach cancer	2.38e-05	0.000133	CcSEcCtD
Thalidomide—Pruritus—Doxorubicin—stomach cancer	2.36e-05	0.000131	CcSEcCtD
Thalidomide—Vomiting—Epirubicin—stomach cancer	2.29e-05	0.000127	CcSEcCtD
Thalidomide—Nausea—Methotrexate—stomach cancer	2.29e-05	0.000127	CcSEcCtD
Thalidomide—Diarrhoea—Doxorubicin—stomach cancer	2.28e-05	0.000127	CcSEcCtD
Thalidomide—Rash—Epirubicin—stomach cancer	2.27e-05	0.000126	CcSEcCtD
Thalidomide—Dermatitis—Epirubicin—stomach cancer	2.27e-05	0.000126	CcSEcCtD
Thalidomide—Headache—Epirubicin—stomach cancer	2.26e-05	0.000126	CcSEcCtD
Thalidomide—Dizziness—Doxorubicin—stomach cancer	2.2e-05	0.000123	CcSEcCtD
Thalidomide—Nausea—Epirubicin—stomach cancer	2.14e-05	0.000119	CcSEcCtD
Thalidomide—Vomiting—Doxorubicin—stomach cancer	2.12e-05	0.000118	CcSEcCtD
Thalidomide—Rash—Doxorubicin—stomach cancer	2.1e-05	0.000117	CcSEcCtD
Thalidomide—Dermatitis—Doxorubicin—stomach cancer	2.1e-05	0.000117	CcSEcCtD
Thalidomide—Headache—Doxorubicin—stomach cancer	2.09e-05	0.000116	CcSEcCtD
Thalidomide—Nausea—Doxorubicin—stomach cancer	1.98e-05	0.00011	CcSEcCtD
Thalidomide—TNF—Developmental Biology—IL6—stomach cancer	4.73e-06	3.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SMAD4—stomach cancer	4.66e-06	3.27e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CD44—stomach cancer	4.66e-06	3.26e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CD44—stomach cancer	4.65e-06	3.26e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6R—stomach cancer	4.64e-06	3.25e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—stomach cancer	4.59e-06	3.22e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—stomach cancer	4.58e-06	3.21e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—STAT3—stomach cancer	4.57e-06	3.21e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALOX5—stomach cancer	4.53e-06	3.18e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SREBF2—stomach cancer	4.5e-06	3.15e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CDKN1A—stomach cancer	4.49e-06	3.15e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ERCC2—stomach cancer	4.49e-06	3.15e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—DPYD—stomach cancer	4.46e-06	3.12e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—RORA—stomach cancer	4.44e-06	3.12e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—stomach cancer	4.43e-06	3.11e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FYN—stomach cancer	4.43e-06	3.1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6R—stomach cancer	4.4e-06	3.09e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CD44—stomach cancer	4.39e-06	3.08e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MAPK3—stomach cancer	4.37e-06	3.06e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SERPINE1—stomach cancer	4.34e-06	3.05e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—STAT3—stomach cancer	4.34e-06	3.04e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTT1—stomach cancer	4.32e-06	3.03e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP2A6—stomach cancer	4.27e-06	3e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	4.26e-06	2.99e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERCC2—stomach cancer	4.26e-06	2.98e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MTHFR—stomach cancer	4.22e-06	2.96e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPP2R1A—stomach cancer	4.21e-06	2.95e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RHOA—stomach cancer	4.19e-06	2.94e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALDOB—stomach cancer	4.16e-06	2.92e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MAPK1—stomach cancer	4.16e-06	2.92e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—stomach cancer	4.16e-06	2.92e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKR1C3—stomach cancer	4.16e-06	2.91e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGFR2—stomach cancer	4.16e-06	2.91e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MAPK3—stomach cancer	4.15e-06	2.91e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOS3—stomach cancer	4.15e-06	2.91e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTP1—stomach cancer	4.13e-06	2.89e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SERPINE1—stomach cancer	4.12e-06	2.89e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—HMOX1—stomach cancer	4.07e-06	2.85e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ENO1—stomach cancer	4.05e-06	2.84e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—stomach cancer	4.04e-06	2.83e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—STAT3—stomach cancer	4.01e-06	2.81e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTHFR—stomach cancer	4e-06	2.8e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—stomach cancer	3.98e-06	2.79e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RHOA—stomach cancer	3.98e-06	2.79e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPP2R1A—stomach cancer	3.96e-06	2.78e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPP2R1A—stomach cancer	3.95e-06	2.77e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MAPK1—stomach cancer	3.95e-06	2.77e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—stomach cancer	3.95e-06	2.77e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTT1—stomach cancer	3.94e-06	2.76e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOS3—stomach cancer	3.93e-06	2.76e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KRAS—stomach cancer	3.93e-06	2.75e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—stomach cancer	3.93e-06	2.75e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—stomach cancer	3.92e-06	2.75e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP2A6—stomach cancer	3.9e-06	2.73e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CAV1—stomach cancer	3.89e-06	2.73e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOA1—stomach cancer	3.88e-06	2.72e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTP1—stomach cancer	3.88e-06	2.72e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB2—stomach cancer	3.88e-06	2.72e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTP1—stomach cancer	3.88e-06	2.72e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALOX5—stomach cancer	3.87e-06	2.71e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TYMS—stomach cancer	3.83e-06	2.69e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HMOX1—stomach cancer	3.83e-06	2.69e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MAPK3—stomach cancer	3.83e-06	2.68e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—HMOX1—stomach cancer	3.82e-06	2.68e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—DPYD—stomach cancer	3.81e-06	2.67e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IRS2—stomach cancer	3.81e-06	2.67e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTM1—stomach cancer	3.79e-06	2.66e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKR1C3—stomach cancer	3.79e-06	2.66e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPP2R1A—stomach cancer	3.73e-06	2.62e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KRAS—stomach cancer	3.73e-06	2.61e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—stomach cancer	3.72e-06	2.61e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	3.72e-06	2.61e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ENO1—stomach cancer	3.69e-06	2.59e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CAV1—stomach cancer	3.69e-06	2.59e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOA1—stomach cancer	3.68e-06	2.58e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB2—stomach cancer	3.68e-06	2.58e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL8—stomach cancer	3.68e-06	2.58e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTP1—stomach cancer	3.66e-06	2.57e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MAPK1—stomach cancer	3.64e-06	2.55e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—stomach cancer	3.64e-06	2.55e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—stomach cancer	3.63e-06	2.55e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HMOX1—stomach cancer	3.61e-06	2.53e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TYMS—stomach cancer	3.61e-06	2.53e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PIK3CA—stomach cancer	3.61e-06	2.53e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TYMS—stomach cancer	3.6e-06	2.53e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CD44—stomach cancer	3.59e-06	2.52e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1B—stomach cancer	3.59e-06	2.52e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTM1—stomach cancer	3.57e-06	2.5e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ERCC2—stomach cancer	3.56e-06	2.5e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTM1—stomach cancer	3.56e-06	2.5e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6ST—stomach cancer	3.5e-06	2.45e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL8—stomach cancer	3.49e-06	2.45e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	3.49e-06	2.44e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—stomach cancer	3.45e-06	2.42e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—stomach cancer	3.44e-06	2.41e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCND1—stomach cancer	3.43e-06	2.4e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PIK3CA—stomach cancer	3.42e-06	2.4e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—stomach cancer	3.42e-06	2.4e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—JUN—stomach cancer	3.42e-06	2.4e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1B—stomach cancer	3.41e-06	2.39e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TYMS—stomach cancer	3.4e-06	2.39e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTT1—stomach cancer	3.37e-06	2.36e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTM1—stomach cancer	3.36e-06	2.36e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APC—stomach cancer	3.36e-06	2.36e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ERCC2—stomach cancer	3.35e-06	2.35e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—stomach cancer	3.35e-06	2.35e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ERCC2—stomach cancer	3.35e-06	2.35e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—stomach cancer	3.34e-06	2.34e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2A6—stomach cancer	3.33e-06	2.33e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—stomach cancer	3.33e-06	2.33e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1A—stomach cancer	3.31e-06	2.32e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CD44—stomach cancer	3.28e-06	2.3e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—stomach cancer	3.25e-06	2.28e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—JUN—stomach cancer	3.24e-06	2.27e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKR1C3—stomach cancer	3.24e-06	2.27e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK8—stomach cancer	3.24e-06	2.27e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—stomach cancer	3.2e-06	2.24e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	3.18e-06	2.23e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—stomach cancer	3.17e-06	2.22e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ERCC2—stomach cancer	3.16e-06	2.22e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PIK3CA—stomach cancer	3.16e-06	2.22e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—stomach cancer	3.16e-06	2.21e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ENO1—stomach cancer	3.16e-06	2.21e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—stomach cancer	3.15e-06	2.21e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—stomach cancer	3.15e-06	2.21e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1A—stomach cancer	3.15e-06	2.21e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6R—stomach cancer	3.12e-06	2.19e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—stomach cancer	3.1e-06	2.18e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CAV1—stomach cancer	3.09e-06	2.17e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOA1—stomach cancer	3.08e-06	2.16e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—stomach cancer	3.08e-06	2.16e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK8—stomach cancer	3.07e-06	2.15e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPP2R1A—stomach cancer	3.05e-06	2.14e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—stomach cancer	3.03e-06	2.13e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTP1—stomach cancer	3e-06	2.1e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—stomach cancer	2.99e-06	2.09e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—stomach cancer	2.97e-06	2.08e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT3—stomach cancer	2.96e-06	2.07e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMOX1—stomach cancer	2.95e-06	2.07e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	2.95e-06	2.07e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—stomach cancer	2.94e-06	2.06e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—stomach cancer	2.92e-06	2.05e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SERPINE1—stomach cancer	2.92e-06	2.05e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CAV1—stomach cancer	2.91e-06	2.04e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CAV1—stomach cancer	2.9e-06	2.04e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOA1—stomach cancer	2.9e-06	2.04e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOA1—stomach cancer	2.9e-06	2.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—stomach cancer	2.83e-06	1.99e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK3—stomach cancer	2.83e-06	1.98e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RHOA—stomach cancer	2.82e-06	1.98e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT3—stomach cancer	2.81e-06	1.97e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—stomach cancer	2.8e-06	1.96e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CD44—stomach cancer	2.8e-06	1.96e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—stomach cancer	2.79e-06	1.96e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TYMS—stomach cancer	2.79e-06	1.95e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPP2R1A—stomach cancer	2.78e-06	1.95e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTM1—stomach cancer	2.75e-06	1.93e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—stomach cancer	2.75e-06	1.93e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CAV1—stomach cancer	2.74e-06	1.92e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOA1—stomach cancer	2.74e-06	1.92e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTP1—stomach cancer	2.73e-06	1.92e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—stomach cancer	2.72e-06	1.9e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	2.72e-06	1.9e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMOX1—stomach cancer	2.69e-06	1.89e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—stomach cancer	2.69e-06	1.89e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK1—stomach cancer	2.69e-06	1.89e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—stomach cancer	2.69e-06	1.88e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK3—stomach cancer	2.68e-06	1.88e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	2.62e-06	1.84e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB2—stomach cancer	2.61e-06	1.83e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—stomach cancer	2.61e-06	1.83e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ERCC2—stomach cancer	2.59e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—stomach cancer	2.56e-06	1.79e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—stomach cancer	2.55e-06	1.79e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK1—stomach cancer	2.55e-06	1.79e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—stomach cancer	2.55e-06	1.79e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—stomach cancer	2.54e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TYMS—stomach cancer	2.54e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTM1—stomach cancer	2.51e-06	1.76e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—stomach cancer	2.44e-06	1.71e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—stomach cancer	2.43e-06	1.71e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1B—stomach cancer	2.42e-06	1.69e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—stomach cancer	2.41e-06	1.69e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—stomach cancer	2.41e-06	1.69e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPP2R1A—stomach cancer	2.38e-06	1.67e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ERCC2—stomach cancer	2.36e-06	1.65e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—stomach cancer	2.34e-06	1.64e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTP1—stomach cancer	2.33e-06	1.64e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CA—stomach cancer	2.33e-06	1.64e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMOX1—stomach cancer	2.3e-06	1.61e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—stomach cancer	2.3e-06	1.61e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—stomach cancer	2.29e-06	1.61e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—stomach cancer	2.26e-06	1.58e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CAV1—stomach cancer	2.24e-06	1.57e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOA1—stomach cancer	2.24e-06	1.57e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1A—stomach cancer	2.23e-06	1.56e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—stomach cancer	2.22e-06	1.56e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CA—stomach cancer	2.21e-06	1.55e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—stomach cancer	2.2e-06	1.54e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—stomach cancer	2.19e-06	1.54e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TYMS—stomach cancer	2.17e-06	1.52e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—stomach cancer	2.17e-06	1.52e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—stomach cancer	2.16e-06	1.51e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTM1—stomach cancer	2.15e-06	1.5e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	2.14e-06	1.5e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—stomach cancer	2.14e-06	1.5e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—stomach cancer	2.07e-06	1.45e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—stomach cancer	2.07e-06	1.45e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—stomach cancer	2.05e-06	1.44e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CAV1—stomach cancer	2.05e-06	1.43e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOA1—stomach cancer	2.04e-06	1.43e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ERCC2—stomach cancer	2.02e-06	1.41e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—stomach cancer	2.01e-06	1.41e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—stomach cancer	2.01e-06	1.41e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STAT3—stomach cancer	1.99e-06	1.4e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—stomach cancer	1.97e-06	1.38e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—stomach cancer	1.96e-06	1.37e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	1.96e-06	1.37e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAPK3—stomach cancer	1.9e-06	1.33e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—stomach cancer	1.9e-06	1.33e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—stomach cancer	1.9e-06	1.33e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—stomach cancer	1.85e-06	1.3e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAPK1—stomach cancer	1.81e-06	1.27e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—stomach cancer	1.81e-06	1.27e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—stomach cancer	1.8e-06	1.26e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—stomach cancer	1.77e-06	1.24e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CAV1—stomach cancer	1.75e-06	1.23e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOA1—stomach cancer	1.74e-06	1.22e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—stomach cancer	1.71e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—stomach cancer	1.7e-06	1.19e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	1.67e-06	1.17e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CA—stomach cancer	1.66e-06	1.16e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—stomach cancer	1.62e-06	1.13e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CA—stomach cancer	1.57e-06	1.1e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—stomach cancer	1.55e-06	1.09e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—stomach cancer	1.55e-06	1.08e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—stomach cancer	1.54e-06	1.08e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—stomach cancer	1.45e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—stomach cancer	1.42e-06	9.92e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—stomach cancer	1.39e-06	9.75e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—stomach cancer	1.38e-06	9.69e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—stomach cancer	1.32e-06	9.27e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CA—stomach cancer	1.31e-06	9.22e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CA—stomach cancer	1.24e-06	8.68e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CA—stomach cancer	1.24e-06	8.66e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—stomach cancer	1.21e-06	8.48e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CA—stomach cancer	1.17e-06	8.18e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CA—stomach cancer	9.55e-07	6.7e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CA—stomach cancer	8.71e-07	6.1e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CA—stomach cancer	7.44e-07	5.22e-06	CbGpPWpGaD
